<DOC>
	<DOCNO>NCT00534313</DOCNO>
	<brief_summary>The purpose study determine optimal abatacept dose regimen treatment active arthritis due psoriatic arthritis patient prior inadequate response disease-modifying antirheumatic drug , include methotrexate tumor necrosis factor alpha-blockade compound .</brief_summary>
	<brief_title>Safety Efficacy Abatacept Versus Placebo Participants With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Meeting classification criterion psoriatic arthritis duration disease least 3 month Prior failure ( inefficacy intolerance ) therapy diseasemodifying antirheumatic drug ; patient prior failure methotrexate , must take least 15 mg per week least 2 month If recent failure ( inefficacy intolerance ) tumor necrosis factor αblockade compound , participant must wash prior first dose : 56 day infliximab 28 day etanercept adalimumab Disease activity define tender joint count ≥3 , swell joint count ≥3 , clinically detectable synovitis screen Day 01 ( prior infusion ) Active psoriasis qualify target lesion ≥2 cm diameter Able undergo magnetic resonance imaging Use appropriate birth control woman child bear potential ( WOCBP ) Key WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 10 week last dose investigational product Women pregnant breastfeeding plan become pregnant start breastfeed duration study Women positive pregnancy test enrollment prior investigational product administration . Participants schedule anticipate joint replacement surgery . Those recent history clinically significant drug alcohol abuse Concomitant illness investigator 's opinion likely require systemic glucocorticosteroid therapy study ( example : moderate severe asthma ) Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , pulmonary , cardiac , neurologic , ophthalmologic , cerebral disease . Unwillingness inability undergo screen base current local country guidelines/standards evaluate presence cancer Cancer within last 5 year Current malignancy sign possible malignancy detect screening procedure workup exclude malignancy complete malignancy exclude At risk history ( within 3 year ) tuberculosis Any serious bacterial infection within last 3 month , treat resolve antibiotic , chronic bacterial infection ( , limit , chronic pyelonephritis , osteomyelitis , bronchiectasis ) Evidence active latent bacterial viral infection infection time potential enrollment Herpes zoster cytomegalovirus resolve less 2 month prior sign inform consent Receipt live vaccine within 3 month anticipate first dose study medication anticipation need live vaccine time 3 month duration study Longterm period participant : Must meet eligibility criterion shortterm period complete shortterm ( 24week ) period study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>